Abstract:Lipid nanoparticles (LNPs) have successfully entered the clinic for the delivery of mRNA- and siRNA-based therapeutics, most recently as vaccines for COVID-19. Nevertheless, there is a lack of understanding regarding their in vivo behavior, in particular cell targeting. Part of this LNP tropism is based on the adherence of endogenous protein to the particle surface. This protein forms a so-called corona that can change, amongst other things, the circulation time, biodistribution and cellular uptake of these particles. The formation of this protein corona, in turn, is dependent on the nanoparticle properties (e.g., size, charge, surface chemistry and hydrophobicity) as well as the biological environment from which it is derived. With the potential of gene therapy to target virtually any disease, administration sites other than intravenous route are considered, resulting in tissue specific protein coronas. For neurological diseases, intracranial administration of LNPs results in a cerebral spinal fluid derived protein corona, possibly changing the properties of the lipid nanoparticle compared to intravenous administration. Here, the differences between plasma and CSF derived protein coronas on a clinically relevant LNP formulation were studied in vitro. Protein analysis showed that LNPs incubated in human CSF (C-LNPs) developed a protein corona composition that differed from that of LNPs incubated in plasma (P-LNPs). Lipoproteins as a whole, but in particular apolipoprotein E, represented a higher percentage of the total protein corona on C-LNPs than on P-LNPs. This resulted in improved cellular uptake of C-LNPs compared to P-LNPs, regardless of cell origin. Importantly, the higher LNP uptake did not directly translate into more efficient cargo delivery, underlining that further assessment of such mechanisms is necessary. These findings show that biofluid specific protein coronas alter LNP functionality, suggesting that the site of administration could affect LNP efficacy in vivo and needs to be considered during the development of the formulation.

Looking back, moving forward: protein corona of lipid nanoparticles

The protein corona and its effects on nanoparticle-based drug delivery systems

Research Progress and Application Opportunities of Nanoparticle-Protein Corona Complexes.

Protein corona, influence on drug delivery system and its improvement strategy: A review

Artificial engineering of the protein corona at bio-nano interfaces for improved cancer-targeted nanotherapy

Nanoparticle protein corona: from structure and function to therapeutic targeting

The role of protein corona on nanodrugs for organ-targeting and its prospects of application

The impact of protein corona on the biological behavior of targeting nanomedicines

The Yin and Yang of the protein corona on the delivery journey of nanoparticles

Towards understanding of nanoparticle–protein corona

Characterization and Biomedical Application Opportunities of the Nanoparticle's Protein Corona

Emerging Well-Tailored Nanoparticulate Delivery System Based on in Situ Regulation of the Protein Corona

The Impact of Protein Corona on the Behavior and Targeting Capability of Nanoparticle-Based Delivery System.

The Interaction Between Nanoparticles-Protein Corona Complex and Cells and Its Toxic Effect on Cells

The protein corona on nanoparticles as viewed from a nanoparticle-sizing perspective.

Biofluid specific protein coronas affect lipid nanoparticle behavior in vitro

Unraveling the impact of different liposomal formulations on the plasma protein corona composition might give hints on the targeting capability of nanoparticles

Modulating the toxicity of engineered nanoparticles by controlling protein corona formation: Recent advances and future prospects

Protein Corona Formation on Colloidal Polymeric Nanoparticles and Polymeric Nanogels: Impact on Cellular Uptake, Toxicity, Immunogenicity, and Drug Release Properties

The Protein Corona on Nanoparticles As Viewed from a Nanoparticle‐sizing Perspective

The Janus of Protein Corona on Nanoparticles for Tumor Targeting, Immunotherapy and Diagnosis